Thanks for your suggestion, I will sell when I think it is right without writing about it in HC.
But as for my intention of writing this "essay", it is to
caution the mum & dad investors, like myself, of possible outcome of this trial from BIT's past records based on facts.
Facts, which will offend some, who unneccessarily upramp the stock to glory and beyond to $30 Billion.
A similar company for comparison on maket valuation:
Gilead bought out a clinical-stage development company Pharmasset (similar to Biotron) for its Hep C Virus treatment drug for $11Billion which was already at a market value of $5 Billion. 24/7 Wall St, a financial news company considered even this is over and above the actual potential worth.
https://www.fiercebiotech.com/biote...s-bags-pharmasset-s-hep-c-pipeline-11b-buyout
The uprampers have been pumping the maket value of Biotron to $30 Billion while its current market value is only under $100 Million. What ambition!!!
Please note: When BIT trumpeted it's success in Hep C Virus treatment success in 2016, neither BIT nor the uprampers disclosed in the HC discussions that the medical world was looking for a Interferon-free treatment - all this time while BIT's claimed success was based on Interferon/Ribavirin. They pulled one, right in fron of the SH's eyes.
Clearly no downramping in my post here, but rather only facts and cautions to fellow share holders.
If BIT comes out with a positive result
& a commercial deal (emphasize on
deal again) I will try and write another essay praising the company.
Until then, be aware of the facts and beware of uprampers.
